Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DRRX Jan 2022 5.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
3.30000.0000 (0.00%)
As of 06:51AM EST. Market open.
Advertisement
Full screen
Previous Close3.3000
Open3.3000
Bid3.6000
Ask4.4000
Strike5.00
Expire Date2022-01-21
Day's Range3.3000 - 3.3000
Contract RangeN/A
Volume10
Open Interest20
  • Zacks

    Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks

    Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • PR Newswire

    DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

    DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

  • PR Newswire

    DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

    DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development and commercialization rights to POSIMIR® (bupivacaine solution) for infiltration use, DURECT's FDA-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery, in the United States.

Advertisement
Advertisement